<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238755</url>
  </required_header>
  <id_info>
    <org_study_id>2016P001999</org_study_id>
    <nct_id>NCT03238755</nct_id>
  </id_info>
  <brief_title>Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study</brief_title>
  <official_title>Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators plan to test whether statins can preserve and/or improve
      diastolic function among asymptomatic persons with HIV who are on anti-retroviral therapy.
      Both myocardial fibrosis and myocardial steatosis are thought to contribute to diastolic
      dysfunction and eventually overt heart failure in HIV. HIV-positive participants will undergo
      cardiac MRI/MRS imaging studies for the evaluation of myocardial fibrosis and myocardial
      steatosis prior to initiation of statin or placebo therapy and then two years after
      initiation of statin or placebo therapy. Traditional markers of cardiovascular (CVD) risk,
      systemic immune activation/ inflammation, HIV-specific parameters (i.e. CD4 count), and
      markers of myocardial stretch/injury will be assessed in relation to cardiac MRI/MRS
      outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular Volume (ECV), a measure of myocardial fibrosis on Cardiac MRI</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic function on Cardiac MRI</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Myocardial Inflammation on Cardiac MRI</measure>
    <time_frame>Two Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intramyocardial fat on Cardiac MRI/MRS</measure>
    <time_frame>Two Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic function on Cardiac MRI</measure>
    <time_frame>Two Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Visceral Adiposity on MRS</measure>
    <time_frame>Two Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Biomarkers (inflammation/ immune markers, hormonal markers) and markers of myocardial stretch</measure>
    <time_frame>Two Years</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Statin group</arm_group_label>
    <description>HIV-infected individuals receiving statin therapy for the duration of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <description>HIV-infected individuals receiving placebo therapy for the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI/MRS</intervention_name>
    <description>whole blood, plasma, and serum</description>
    <arm_group_label>Statin group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma, and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected subjects on ART from the community
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New enrollment in the REPRIEVE Trial

        Exclusion Criteria:

          -  clinical diagnosis of HFpEF or HFrEF, by subject report

          -  standard contraindications to MRI procedure based on MRI Patient Procedure Screening
             Form - including history of severe allergy to gadolinium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tomas Neilan, MD</last_name>
    <phone>617-724-5351</phone>
    <email>tneilan@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markella Zanni, MD</last_name>
    <phone>617-724-6926</phone>
    <email>mzanni@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Medical Center-Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberta Warner</last_name>
      <phone>310-268-3643</phone>
      <email>Alberta.Warner@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Neilan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UTSW Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamta Jain</last_name>
      <email>mamta.jain@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tomas Neilan, MD</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Diastolic Dysfunction</keyword>
  <keyword>Myocardial fibrosis</keyword>
  <keyword>Statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

